Visser C A, Jaarsma W, Kan G, Koolen J J, Lie K I
Br J Clin Pharmacol. 1985;20 Suppl 1(Suppl 1):158S-162S. doi: 10.1111/j.1365-2125.1985.tb05159.x.
Haemodynamic effects of nicardipine were studied in 12 patients with documented coronary artery disease. Following nicardipine 10 mg, given intravenously to patients at rest, the heart rate increased, mean arterial pressure decreased, cardiac index increased, and systemic vascular resistance decreased significantly. Compared with the control exercise values, significant increases in heart rate and cardiac index and significant decreases in mean arterial pressure, systemic vascular resistance, and left ventricular end diastolic pressure occurred when nicardipine, 10 mg i.v., was given to the patients during exercise. All 12 patients complained of angina during the exercise phase, but following treatment with nicardipine, 10 mg i.v., only four patients reported angina when exercising to the same level. Exercise capacity on oral nicardipine treatment tended to increase whilst the ejection fraction response to exercise did not change. Thus, nicardipine was a potent vasodilator, which produced a marked reduction of systemic vascular resistance and left ventricular end diastolic pressure during exercise.
在12例确诊为冠状动脉疾病的患者中研究了尼卡地平的血流动力学效应。给静息状态的患者静脉注射10mg尼卡地平后，心率增加，平均动脉压降低，心脏指数增加，全身血管阻力显著降低。与对照运动值相比，给运动中的患者静脉注射10mg尼卡地平后，心率和心脏指数显著增加，平均动脉压、全身血管阻力和左心室舒张末期压力显著降低。所有12例患者在运动阶段均出现心绞痛，但静脉注射10mg尼卡地平治疗后，仅4例患者在运动至相同水平时报告有心绞痛。口服尼卡地平治疗时运动能力有增加趋势，而运动时射血分数反应未改变。因此，尼卡地平是一种强效血管扩张剂，在运动期间可使全身血管阻力和左心室舒张末期压力显著降低。
